Medis El to reacquire US rights to CellScan:
This article was originally published in Clinica
Executive Summary
Israeli diagnostic company Medis El has the option to reacquire the US distribution rights to CellScan under an agreement with US shareholder Cell Diagnostics (CDI). Medis will receive $500,000 from CDI on July 1st, as the first repayment of a $2.5 million note. Medis will cancel the unpaid $2 million if it exercises the option to CellScan. Medis says the US rights will be an asset in its search for an international marketing partner for the cancer screening system.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.